二甲双胍对糖耐量减低患者血糖及心血管致病因素的影响

Effect of metformin on the blood glucose and cardiovascular disease in the impaired glucose tolerance population

目的了解二甲双胍在糖耐量减低(IGT)患者中的作用,探讨其对血糖和心血管致病因素的影响。方法对86例IGT患者随机分成2组,治疗组49例,给予二甲双胍(750mg/d)干预治疗试验,对照组37例,不用药物干预,随访观察1年。结果86例患者有81例完成随访,对照组36例,二甲双胍治疗组45例,治疗组空腹血糖(FBG),餐后2h血糖(PBG),糖化血红蛋白(HBA1C),体重指数(BMI)较对照组明显降低(P<0.01)。2.二甲双胍治疗组IGT转变为2型糖尿病4例(8.89%),对照组有11例转变为2型糖尿病(30.55%),后者明显增加(P<0.01)。3.治疗组心血管事件的发生率为13.33%,对照组为36.1%。结论二甲双胍不仅可以延缓糖尿病的发生,还可以减少糖耐量减低患者心血管疾病的致病因素,从而减少心血管事件的发生。

Objective To investegate the effect of mefformin on the blood glucose and cardiovascular disease in the impaired glucose tolerance population. Methods Eight-six people with impaired glucose tolerance were randomly derided into metformin treatment group and control group. The former with 49 people were treated with mefformin 750 mg per day and the other group with 37 people were not intervened in. Results After being followed up for a year,81 people were finished with the study. Compared with the control group,the FBG,PBG, HbA1C and BMI in metformin treatment group were lower apparently （ P 〈 0.01 ）. Conclusion Mefformin can delay the development of diabetes and decrease the risk factor of cardiovascular disease.